Second, for patients with AMI and comorbid heart failure, physicians tend to add drugs such as ARNI and SGLT2 inhibitors during the hospitalization period; the widespread use of these drugs may have diminished the effect of ivabradine. Here, SLC5A2 is linked to heart failure.